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Abstract
Endothelial dysfunction and vascular insulin resistance usually coexist and chronic inflammation engenders both. In
the present study, we investigate the temporal relationship between vascular insulin resistance and metabolic
insulin resistance. We assessed insulin responses in all arterial segments, including aorta, distal saphenous artery
and the microvasculature, as well as the metabolic insulin responses in muscle in rats fed on a high-fat diet (HFD)
for various durations ranging from 3 days to 4 weeks with or without sodium salicylate treatment. Compared with
controls, HFD feeding significantly blunted insulin-mediated Akt (protein kinase B) and eNOS [endothelial nitric oxide
(NO) synthase] phosphorylation in aorta in 1 week, blunted vasodilatory response in small resistance vessel in
4 weeks and microvascular recruitment in as early as 3 days. Insulin-stimulated whole body glucose disposal did
not begin to progressively decrease until after 1 week. Salicylate treatment fully inhibited vascular inflammation,
prevented microvascular insulin resistance and significantly improved muscle metabolic responses to insulin. We
conclude that microvascular insulin resistance is an early event in diet-induced obesity and insulin resistance and
inflammation plays an essential role in this process. Our data suggest microvascular insulin resistance contributes
to the development of metabolic insulin resistance in muscle and muscle microvasculature is a potential
therapeutic target in the prevention and treatment of diabetes and its related complications.
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INTRODUCTION
The prevalence of obesity and obesity-related diabetes has
reached a global epidemic and chronic inflammation has been
recognized as a key player in the development of insulin res-
istance and diabetes [1–4]. Growing evidence from both clin-
ical and animal studies has suggested that endothelial dysfunc-
tion and vascular insulin resistance coexist in obesity and dia-
betes and they may play a causative role in the development
of metabolic insulin resistance [5–9] in addition to accelerat-
ing diabetes-related cardiovascular complications [10,11]. This is
particularly true in the setting of microvasculature as it provides
endothelial exchange surface area for substrate exchanges and
metabolic waste removal and thus profoundly affects cell meta-
bolism, function and health. Muscle microvasculature is also
insulin-responsive and ample evidence has confirmed that it
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has a critical role in regulating muscle insulin action [12–18].
In healthy humans or laboratory animals, insulin at physiolo-
gical concentrations potently recruits muscle microvasculature
and expands the endothelial exchange surface area, leading to
increased muscle delivery and action of insulin [12,19]. These
actions are impaired in humans with moderate obesity, humans
receiving lipid infusion and in rodents with either genetic or
experimentally induced insulin resistance [20–24]. The impair-
ment of insulin’s microvascular action has been implicated in the
development of metabolic insulin resistance in muscle as insulin-
mediated microvascular recruitment occurs earlier than insulin-
stimulated muscle glucose uptake in vivo and blockade of the
insulin’s vasodilatory action reduces insulin-stimulated glucose
disposal by up to 40 % [25], and all metabolic insulin resistance
inducers have been shown to cause microvascular insulin resist-
ance as well [26,27]. However, the temporal relationship between
C© 2015 Authors; published by Portland Press Limited 1025
L. Zhao and others
microvascular and metabolic insulin resistance has not been
explored.
Obesity is associated with chronic inflammation which plays
a key role in the pathogenesis of insulin resistance. Inhibitor
of nuclear factor κB (IκB) kinase β (IKKβ) is a serine kinase
that controls the activation of nuclear factor κB (NF-κB) and
is the critical node linking inflammation to obesity-induced in-
sulin resistance [28,29]. Activation of IKKβ leads to increased
phosphorylation and degradation of IκB with subsequent NF-
κB activation and cellular inflammatory responses, leading to
impaired insulin signalling in both key metabolic organs (liver,
adipose tissue and skeletal muscle) and vasculature in animal
models of diet-induced obesity [5,28]. Inhibition of the NF-κB
inflammation pathway using salicylate, a potent IKKβ inhib-
itor reverses obesity- and diet-induced insulin resistance, blocks
lipid infusion-induced metabolic insulin resistance in laboratory
animals [30,31], and improves glycaemic control in obese non-
diabetic adults [32,33]. Our group has previously reported that
salsalate attenuates non-esterified fatty acid-induced microvas-
cular and metabolic insulin resistance in humans [34]. Whether
inhibition of the inflammation pathway differentially affects in-
sulin’s vascular actions compared with metabolic actions has not
been examined.
In the present study, we explored the temporal relationship
among vascular inflammation, vascular and muscle metabolic
insulin resistance in rats fed on a high-fat diet (HFD) for vari-
ous durations ranging from 3 days to 4 weeks with or without
simultaneous sodium salicylate treatment. Our results reveal that
muscle microvascular insulin resistance is an early event in the
development of diet-induced obesity and inhibition of the NF-
κB pathway with sodium salicylate fully restores microvascular
insulin responses and ameliorates metabolic insulin resistance in
the setting of HFD feeding.
MATERIALS AND METHODS
Animal preparations and experimental protocols
Adult male Sprague–Dawley rats (∼200–250 g, Charles River
Laboratories) were placed on an HFD (60 % calories from sat-
urated fat, Research Diets) with or without administration of
sodium salicylate (120 mg/kg/day) by oral gavage for 3 days,
1 week, 2 weeks or 4 weeks. At the dose selected, sodium sali-
cylate potently inhibits NF-κB activity [31]. Additional rats were
fed on a chow diet as controls. Rats were housed at 22 +− 2 ◦C,
on a 12-h light/12-h dark cycle and given water ad libitum. After
the feeding period, rats were starved overnight and anaesthetized
with pentobarbital sodium [50 mg/kg i.p. (intraperitoneally), Ab-
bott Laboratories]. They were then placed in a supine position on a
heating pad to ensure euthermia and intubated to maintain a patent
airway. The carotid artery and the jugular vein were cannulated
with PE50 polyethylene tubing (Fisher Scientific) for blood pres-
sure monitoring, arterial blood sampling and various infusions.
After a 30–45 min baseline period to ensure haemodynamic sta-
bility and stable anaesthesia, rats received a 2-h euglycaemic–
hyperinsulinaemic clamp (3 milliunits/kg/min). Arterial blood
glucose was determined every 10 min using an Accu-Chek Ad-
vantage glucometer (Roche Diagnostics) and 30 % dextrose was
infused at a variable rate to maintain blood glucose within 10 %
of basal levels. Steady-state whole body glucose disposal rates
were calculated. Hind-limb muscle microvascular blood volume
(MBV), microvascular flow velocity (MFV) and microvascular
blood flow (MBF) were determined at 0, 30, 60 and 120 min us-
ing contrast-enhanced ultrasound (CEU), as described previously
[12,15]. Rats were then killed with anaesthetic overdose, gast-
rocnemius muscle and aorta were removed and freeze-clamped
for later measurement of inflammation and insulin signalling
molecules using Western blot analysis, as described below. Distal
saphenous arteries were dissected immediately after the rats were
killed and used for myograph studies.
Throughout the study, mean arterial blood pressure (MAP)
was monitored via a sensor connected to the carotid arterial cath-
eter (Harvard Apparatus and AD Instruments). Pentobarbital so-
dium was infused throughout the study at a variable rate to main-
tain steady levels of anaesthesia and blood pressure. The investig-
ation conformed to the Guide for the Care and Use of Laboratory
Animals published by the National Institutes of Health (Public-
ation No. 85-23, revised 1996) and the study protocols were ap-
proved by the Animal Care and Use Committee of the University
of Virginia.
Measurement of plasma nitric oxide contents
Plasma nitric oxide (NO) levels were measured using a 280i Nitric
Oxide Analyzer (GE Analytical Instruments), according to the
manufacturer’s instructions. In brief, ice-cold ethanol was mixed
with plasma samples at a ratio of 2:1, kept at 0 ◦C for 30 min and
then centrifuged at ∼16 000 g for 5 min. The supernatant was then
used for NO analysis based on a gas-phase chemiluminescent
reaction between NO and ozone.
Determination of plasma cholesterol,
triacylglycerol and insulin levels
Fasting total plasma cholesterol and triacylglycerol levels were
determined using a DCL Total Cholesterol Assay Kit and
Roche Diagnostics Triglyceride Assay. Plasma insulin concen-
trations were measured using a rat insulin ELISA assay kit
(Mercodia AB).
Myograph studies
After removing the adhering connective tissue, distal saphenous
artery was cut into segments of ∼2 mm in length and vessel
functions were measured as previously described [35]. Briefly,
each segment was mounted in a Multi Myograph System (Dan-
ish Myo Technology). The organ chamber was filled with 6 ml of
physiological salt solution buffer (130 mM NaCl, 4.7 mM KCl,
1.6 mM CaCl2, 1.17 mM MgSO4, 1.18 mM KH2PO4, 14.9 mM
NaHCO3, 0.026 mM EDTA and 5.5 mM glucose, pH 7.4), which
was constantly bubbled with 95 % O2/5 % CO2 and maintained at
37 ◦C. Each ring was stretched initially to an optimal tension
(5 mN) and then allowed to stabilize at baseline tone. After
pre-constriction with phenylephrine (2 μM), vasodilatory re-
sponses to acetylcholine (Ach), sodium nitroprusside (SNP) and
insulin were recorded.
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NF-κB DNA-binding activity
Fresh aorta tissues were used for determination of NF-κB activ-
ity as described in [36]. Nuclear extracts from aorta were ob-
tained by using nuclear extraction kits (Active Motif). The
DNA-binding activity of the NF-κB p65 subunit was determ-
ined by ELISA (Active Motif) according to the manufacturer’s
instructions.
Determination of protein expression and
phosphorylation in muscle and aorta
Total eNOS (endothelial NO synthase), Akt (protein kinase B),
ERK1/2 (extracellular-signal-regulated protein kinase 1 and 2)
and β-actin and phosphorylation of eNOS, Akt, ERK1/2 and
IκBα in gastrocnemius and/or aorta were determined using West-
ern blot analysis, as previously described [12,37]. Primary anti-
bodies against phospho-eNOS (Ser1177), total eNOS, phospho-
Akt (Ser473), total Akt, phospho-ERK (Thr202/Tyr204) and total
ERK1/2, β-actin and phospho-IκBα were purchased from Cell
Signaling Technology. All blots were developed using ECL (GE
Healthcare Bio-Sciences). Chemiluminescence blot images were
captured using the UVP imaging system and quantified using
ImageQuant 3.3 software. For protein phosphorylation analyses,
both the total and the phospho-specific densities were quantified
and the ratios of phospho-specific to total density were calculated.
Statistical analysis
All data are presented as means +− S.E.M. Statistical analyses
were performed with SigmaStat 11.0 software (Systat Software),
using either Student’s t test or ANOVA with post-hoc analysis
as appropriate. A P-value of <0.05 was considered statistically
significant.
RESULTS
Effect of HFD feeding on body weight gain and
plasma parameters
Compared with chow diet, rats fed on an HFD gained a similar
amount of weight and had similar fasting plasma glucose concen-
trations (Table 1). In rats fed on the HFD, fasting plasma levels of
triacylglycerols, cholesterol and insulin increased steadily over
the 4-week feeding period and were significantly higher at the end
than those rats on a chow diet. Salicylate treatment did not sig-
nificantly affect body weight gain but decreased fasting plasma
triacylglycerol, cholesterol and insulin levels to the levels seen in
chow-diet rats.
Effects of HFD and sodium salicylate on insulin and
NF-κB signalling in aorta
We first examined the time course of insulin signalling in large
conduit vessel (aorta) using insulin-mediated Akt, eNOS and
ERK1/2 phosphorylation as indices (Figure 1). Insulin potently
stimulated Akt phosphorylation in all control animals and in rats
fed on the HFD for 3 days (P < 0.05 for all). However, insulin-
mediated Akt phosphorylation was totally abolished in rats fed on
the HFD for 1 week and beyond, which was reversed completely
by salicylate administration. Insulin significantly increased aortic
ERK phosphorylation and this effect was not affected by either
HFD feeding or the combination of the HFD and salicylate. On
the contrary, insulin effects on aortic eNOS phosphorylation fol-
lowed exactly the same pattern as Akt phosphorylation in that
HFD abolished insulin-stimulated eNOS phosphorylation after
1 week, but this was again prevented by salicylate treatment.
As prior study showed that aortic inflammation is an early
event in diet-induced obesity [5], we determined aortic IκBα
phosphorylation (a surrogate of IKKβ activation) and NF-κB
DNA-binding activity. As shown in Figures 1(G), 1(F) and
1(I), HFD progressively increased aortic IκBα phosphorylation
and p65 DNA-binding activity (P < 0.05, ANOVA) and sodium
salicylate treatment effectively restored these inflammatory re-
sponses to the control levels.
HFD induces endothelial dysfunction and insulin
resistance in small resistance arteries which can
be prevented by sodium salicylate
We next examined ex vivo the time course of endothelial dysfunc-
tion and insulin resistance induced by HFD feeding and whether
sodium salicylate treatment can prevent their occurrence in isol-
ated distal saphenous arteries (Figure 2). The HFD did not in-
duce a significant impairment in the vasodilatory responses to
Ach until week 4 and this impairment was reversed by admin-
istration of sodium salicylate (Figures 2A–2D). Similarly, the
vasodilatory response to insulin remained unaffected until week
4 and again simultaneous administration of sodium salicylate im-
proved insulin responses almost back to the levels seen in controls
(Figures 2E–2H). Thus, resistance artery insulin resistance lags
behind that in large conduit artery aorta.
Time course of HFD and sodium salicylate on
microvascular insulin responses
Previous evidence suggests that microvascular recruitment is an
early action of insulin which occurs much sooner than insulin-
mediated muscle glucose uptake [12] and accounts for up to 40 %
of insulin-stimulated glucose disposal during insulin infusion
[25]. We thus determined the time course of microvascular insulin
resistance development in the setting of HFD feeding. As shown
in Figure 3, insulin potently recruited muscle microvasculature
as evidenced by a significant increase in muscle MBV in all
control animals (∼60 %, P < 0.05). This effect was blunted by
HFD feeding in as little as 3 days and abolished at 1 week and
beyond (P < 0.05 for all). Simultaneous administration of sodium
salicylate fully restored muscle microvascular insulin responses.
Neither HFD feeding nor HFD and sodium salicylate treatment
altered muscle MFV. As such, muscle MBF followed a similar
pattern (Figure 4).
As insulin-stimulated microvascular recruitment is NO-
dependent, we determined plasma NO contents before and after
insulin clamps in all groups (Figure 5). Insulin infusion po-
tently increased plasma NO contents in all control groups.
Although HFD feeding did not alter basal NO levels, it blunted
insulin-stimulated increase in NO production in as little as 3 days
and totally abolished it after 1 week, a pattern that is similar to mi-
crovascular responses in HFD animals (Figures 3 and 4). Sodium
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Figure 1 Effects of HFD +− sodium salicylate on insulin and NF-κB signalling in aorta
(A and B) Akt phosphorylation, (C and D) ERK1/2 phosphorylation, (E and F) eNOS phosphorylation, (G and H) IκBα
phosphorylation and (I) NF-κB DNA-binding activity. (A, C, E and G) Representative Western blots; (B, D, F and H) quantitative
measurements. Compared with respective control without insulin, *P < 0.05. n = 3–4.
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Table 1 Body weight gain and fasting plasma parameters
Values are means +− S.E.M.; HFD + S: HFD + salicylate. n=5–6.
3 Days 1 Week 2 Weeks 4 Weeks
Body weight gain (g) Chow 27.6 +− 3.2 64.0 +− 5.4 135.4 +− 6.6 218.4 +− 9.5
HFD 28.1 +− 3.1 65.6 +− 8.4 151.4 +− 12.7 239.2 +− 10.9
HFD + S 28.6 +− 3.1 53.6 +− 3.4 118.3 +− 7.7 203.7 +− 11.2
Glucose (mmol/l) Chow 4.79 +− 0.09 4.53 +− 0.08 4.92 +− 0.09 4.99 +− 0.10
HFD 4.76 +− 0.09 4.60 +− 0.13 4.78 +− 0.24 4.73 +− 0.16
HFD + S 4.92 +− 0.12 4.32 +− 0.12 4.63 +− 0.15 4.67 +− 0.08
Triacylglycerols (mmol/l) Chow 0.46 +− 0.06 0.47 +− 0.08 0.53 +− 0.02 0.50 +− 0.03
HFD 0.49 +− 0.05 0.50 +− 0.05 0.53 +− 0.02 0.56 +− 0.04*
HFD + S 0.45 +− 0.04 0.51 +− 0.03 0.50 +− 0.02 0.55 +− 0.06
Total cholesterol (mmol/l) Chow 0.99 +− 0.05 1.19 +− 0.06 1.11 +− 0.15 1.37 +− 0.13
HFD 0.99 +− 0.07 1.13 +− 0.06 1.23 +− 0.08 1.59 +− 0.19*
HFD + S 1.04 +− 0.07 1.20 +− 0.05 1.06 +− 0.08 1.44 +− 0.10
Insulin (pmol/l) Chow 87.6 +− 6.52 83.8 +− 6.1 94.4 +− 5.9 102.0 +− 10.9
HFD 90.3 +− 11.4 93.2 +− 8.2 125.1 +− 12.3 139.8 +− 7.5*
HFD + S 97.2 +− 6.0 103.1 +− 6.6 128.1 +− 9.8 127.2 +− 6.8
*P < 0.05 compared with chow.
salicylate treatment did not change basal plasma NO contents
but fully restored insulin-stimulated NO production in all HFD-
fed rats, again a pattern paralleling the improved microvascular
insulin responses in these rats.
Time course of HFD and sodium salicylate on
muscle metabolic insulin responses
Finally, we assessed muscle metabolic insulin sensitivity by cal-
culating glucose infusion rate during the insulin clamps and
Western blot analysis of Akt and ERK1/2 phosphorylation in
muscle in all study animals. As shown in Figure 6, com-
pared with chow-fed controls, insulin-stimulated glucose dis-
posal did not change significantly before day 3 but then de-
clined significantly and progressively afterwards (by ∼20 % at
week 1, ∼40 % at week 2 and ∼60 % at week 4, P < 0.05
for all) in HFD-fed rats. Animals that received the HFD
and sodium salicylate exhibited a marked improvement in
insulin-stimulated glucose disposal by week 2 (∼50 % increase)
and week 4 (∼70 % increase; P < 0.05 for both). Interest-
ingly, neither HFD nor HFD plus sodium salicylate affected
insulin-mediated Akt or ERK1/2 phosphorylation in muscle
(Figure 7).
DISCUSSION
Insulin resistance is a key feature of obesity-related diabetes
and develops in multiple organs, including skeletal muscle and
vasculature. Evidence thus far has confirmed that vascular dys-
function and insulin resistance coexist and both contribute to the
pathogenesis of diabetes and its cardiovascular complications.
Furthermore, muscle microvasculature plays a pivotal role in the
regulation of muscle insulin delivery and action. In the present
study, we explored the temporal relationship between vascular
inflammation, vascular insulin resistance and metabolic insulin
resistance in rats fed on an HFD for various durations ranging
from 3 days to 4 weeks, using a combination of euglycaemic–
hyperinsulinaemic clamp, Western blotting, myograph study and
CEU techniques. We found that microvascular insulin resistance
is an early event in diet-induced obesity and insulin resistance
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Figure 2 Effects of HFD +− sodium salicylate on resistance arterial endothelial function and insulin responses
Vasodilatory responses to Ach (A–D) and insulin (E–H) were determined using distal saphenous arteries that were dissected
from rats fed on either chow or an HFD for 3 days (A), 1 week (B), 2 weeks (C) and 4 weeks (D). Compared with chow,
*P < 0.05. Compared with HFD, #P < 0.05. n = 5–6.
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Figure 3 Time course effect of HFD +− sodium salicylate on insulin-mediated changes in muscle MBV
Each rat received a 2-h euglycaemic–hyperinsulinaemic clamp after an HFD for 3 days (A), 1 week (B), 2 weeks (C) and
4 weeks (D) with or without simultaneous sodium salicylate treatment. MBV was measured using CEU at baseline and
30, 60 and 120 min after the initiation of insulin infusion. Rats fed normal chow were used as a control. Compared with
respective baseline (0 min), *P < 0.05. n = 5–6.
and inhibition of the NF-κB inflammation pathway with sodium
salicylate effectively reduces vascular inflammation, completely
restores vascular insulin responses and significantly improves
metabolic insulin sensitivity in HFD-fed rodents. Thus, our res-
ults clearly indicate that microvasculature is an early responder
to inflammation during the development of diet-induced insulin
resistance and obesity.
Our observation that during HFD feeding insulin-stimulated
Akt and eNOS phosphorylation did not decrease in aorta until
1 week and insulin-induced resistance vessel relaxation was not
impaired until 4 weeks but microvascular insulin resistance oc-
curred in as little as 3 days suggests that the timeline of vascular
insulin resistance development varies among different arterial
segments and microvasculature is more susceptible to inflam-
matory insult. However, several caveats exist. First, aorta and
small resistance vessels include both endothelial cells and vascu-
lar smooth muscle cells, whereas microvasculature is mostly lined
with only endothelial cells. Secondly, different techniques were
used to assess insulin responses in different arterial segments.
Certainly, it would be ideal to use the same technique to assess
insulin responses but it is technically impossible and physiolo-
gically irrelevant given different arterial segments have different
structures and functions. That the pattern changes were consist-
ent within each vascular segments, i.e. the changes in aortic Akt
and eNOS phosphorylation, the ex vivo vasodilatory responses
to Ach and insulin in isolated distal saphenous artery and the
changes in muscle MBV and MBF with those of plasma NO
contents strongly argues that the variation in insulin resistance
timeline among arterial segments is real.
Previous studies have confirmed that microvasculature crit-
ically regulates insulin’s delivery to and action in muscle
and expansion of muscle MBV induced by factors such as
adiponectin, angiontensin-(1–7), glucagon-like peptide 1, losar-
tan and muscle contraction are associated with increased muscle
insulin action [14,15,17,38,39]. In contrast, factors causing
metabolic insulin resistance are also able to induce microvascu-
lar insulin resistance [26,27]. Our observation that microvascular
insulin resistance occurs earlier than muscle metabolic insulin
resistance is intriguing and suggests that the former may con-
tribute to the pathogenesis of the latter. Our results are clearly
consistent with a prior report demonstrating that HFD feeding
caused insulin resistance in aorta in 1 week but it took those
mice 4–8 weeks to develop insulin resistance in muscle, liver and
adipose tissue [5]. Indeed, in C57BL/6 mice fed on an HFD for
1.5, 3, 6 and 20 weeks, glucose infusion rates and muscle glucose
uptake did not decrease significantly until week 3 despite both
leptin and resistin being elevated in week 1.5 [40]. In a different
study also conducted in HFD-fed mice, muscle glucose uptake
C© 2015 Authors; published by Portland Press Limited 1031
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Figure 4 Time course effect of HFD +− sodium salicylate on insulin-mediated changes in muscle MBF
Each rat received a 2-h euglycaemic–hyperinsulinaemic clamp after an HFD for 3 days (A), 1 week (B), 2 weeks (C) and
4 weeks (D) with or without simultaneous salicylate treatment. MBF was calculated at baseline and 30, 60 and 120 min
after the initiation of insulin infusion. Rats fed normal chow were used as a control. Compared with respective baseline
(0 min), *P < 0.05. Compared with HFD at the same time point, #P < 0.05. n = 5–6.



































Figure 5 Effects of HFD +− sodium salicylate on plasma NO contents
Compared with respective control without insulin, *P < 0.05. n = 5–6.
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Figure 6 Time course effect of HFD +− sodium salicylate on metabolic insulin sensitivity
Each rat received a 2-h euglycaemic–hyperinsulinaemic clamp after an HFD for 3 days (A), 1 week (B), 2 weeks (C) and
4 weeks (D) with or without simultaneous sodium salicylate treatment and the glucose infusion rates (GIR) were recorded.
Compared with baseline, *P < 0.05. Compared with HFD, #P < 0.05. n = 5–6.
again did not decrease until week 3 [41]. Thus, our results firmly
place the vascular endothelium at the forefront of the inflamma-
tion and insulin-resistance rampage.
Sodium salicylate, by specifically binding to IKKβ, reduces
ATP binding and thus inhibits IKKβ activity which leads to
increased IκB phosphorylation and degradation and transloca-
tion of NF-κB to the nucleus [30]. In the present study, we
observed that sodium salicylate potently inhibited HFD-induced
IκBα phosphorylation and completely restored microvascular in-
sulin responses, insulin-mediated Akt and eNOS phosphorylation
in aorta and vasodilatory responses to insulin in the resistance
artery. Together with prior findings in diet-induced obesity mice
that it took 1 week for IκBα phosphorylation to increase in aorta,
8 weeks in liver and muscle and 14 weeks in adipose tissue [5],
our results confirm an essential role of inflammation in the patho-
genesis of vascular insulin resistance in all segments of the arterial
tree. It is worth mentioning that c-Jun N-terminal kinase (JNK),
another key player in obesity-induced inflammation, may also
contribute to obesity-induced vascular inflammation and insulin
resistance which warrant further investigation [42].
Consistent with prior studies showing that treatment of ro-
dents with salicylates attenuates obesity- and diet-induced in-
sulin resistance in muscle [31,43], we found in the present study
that metabolic insulin resistance improved significantly with so-
dium salicylate treatment, as evidenced by a marked increase in
insulin-mediated glucose disposal. That muscle metabolic insulin
responses were not fully restored despite a complete restoration of
vascular insulin responses is consistent with previous evidence
that the maximal contribution of microvasculature to insulin-
mediated metabolic effect (glucose disposal) is <40 % [25]. This
is certainly in agreement with clinical trials showing that salsal-
ate treatment improves glycaemia and insulin-mediated glucose
disposal in obese and diabetic humans without restoring plasma
glucose concentrations back to normal in patients with Type 2
diabetes mellitus (T2DM) [44–46].
It is of interest to note that HFD decreased aortic eNOS and
Akt phosphorylation but not muscle Akt phosphorylation des-
pite a marked decrease in glucose infusion rates. This is not
surprising as prior studies have shown that Akt is not the crit-
ical node in muscle insulin resistance. Insulin activation of Akt
isoforms is normal in muscle of obese non-diabetic and dia-
betic subjects despite a marked decrease in IRS-1- and IRS-
2-associated phosphoinositide 3-kinase (PI3K) activities (∼50 %
and 40 % respectively) and in insulin-stimulated glucose disposal
(∼60 %) in obese diabetic subjects [47]. In mice fed on an HFD
for either 1 or 3 weeks, insulin-stimulated Akt phosphorylation
in liver, adipose tissue and muscle was as same as that in chow-
fed rats [41]. Similarly, we have previously observed in lipid-
infused rats insulin-stimulated muscle Akt phosphorylation was
similar between the control and lipid-infusion groups despite
C© 2015 Authors; published by Portland Press Limited 1033

























* * * * *





















* * * * * * *
* *
3 Days 1 Week 2 Weeks 4 Weeks
Chow HFD HFD+S
















Chow Chow +Ins HFD
HFD +Ins HFD+S HFD+S+Ins













Figure 7 Effects of HFD +− sodium salicylate on skeletal muscle insulin signalling
(A) Akt phosphorylation; (B) ERK1/2 phosphorylation. Compared with respective control without insulin, *P < 0.05. n = 3.
a marked decrease in insulin-mediated glucose disposal in the
latter [38].
In conclusion, our results demonstrate that microvascular in-
sulin resistance is an early event in diet-induced obesity and
inflammation plays an essential role in this process. As muscle
microvasculature critically regulates muscle insulin delivery and
action, microvascular insulin resistance may play a causative role
in the development of muscle metabolic insulin resistance and
early intervention aimed at reducing microvascular insulin resist-
ance may help prevent and/or treatment diabetes and its associated
complications.
CLINICAL PERSPECTIVES
• Evidence from both clinical and animal studies has confirmed
the presence of endothelial dysfunction and insulin resistance
in muscle microvasculature in obesity and diabetes which may
play a causative role in the development of metabolic insulin
resistance.
• The present study explores the temporal relationship between
microvascular and metabolic insulin resistance and shows that
inflammation-induced microvascular insulin resistance is an
early event in diet-induced obesity and plays a causative role
in the development of metabolic insulin resistance.
• These findings help us better understand the pathogenesis of
obesity-associated insulin resistance and are of physiological
as well as clinical importance as microvasculature controls the
delivery of oxygen, nutrient and hormones into tissue and their
exchanges between plasma and tissue interstitium by provid-
ing an endothelial exchange surface area. Thus, early inter-
vention aimed at reducing microvascular insulin resistance
may help to prevent and/or treat diabetes and its associated
complications.
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